Coenzyme M
Coenzyme M structure
|
Common Name | Coenzyme M | ||
|---|---|---|---|---|
| CAS Number | 45127-11-5 | Molecular Weight | 282.379 | |
| Density | 1.8±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C4H10O6S4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
|
Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N.
Cancer Chemother. Pharmacol. 67(2) , 381-91, (2011) Previous studies from our laboratory have identified a role for gamma-glutamyl transpeptidase (GGT) in BNP7787 (disodium 2,2'-dithio-bis ethane sulfonate, dimesna, Tavocept™)-mediated cisplatin nephroprotection. Dekant has proposed that gamma-glutamyl transpe... |
|
|
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
J. Thorac. Oncol. 3(10) , 1159-65, (2008) We investigated dose-dense docetaxel and cisplatin in patients with measurable non-small cell lung cancer in a randomized phase II study without [A] or with [B] a putative chemoprotective agent, BNP7787.Chemotherapy-naive patients with stage IIIB (effusion) o... |
|
|
New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
Cancer Chemother. Pharmacol. 52 Suppl 1 , S3-15, (2003) Any approach applied to drug discovery and development by the medical community and pharmaceutical industry has a direct impact on the future availability of improved, novel, and curative therapies for patients with cancer. By definition, drug discovery is a ... |
|
|
Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase.
Cancer Chemother. Pharmacol. 65(5) , 941-51, (2010) The mechanisms for cisplatin-induced renal cell injury have been the focus of intense investigation for many years with a view to provide a more effective and convenient form of nephroprotection. BNP7787 (disodium 2,2'-dithio-bis ethane sulfonate; dimesna, Ta... |
|
|
Vibrational spectroscopic studies of mesna and dimesna.
Spectrochim. Acta. A. Mol. Biomol. Spectrosc. 59(8) , 1791-8, (2003) Raman, and infrared spectra of mesna and dimesna have been collected in the present spectroscopic studies. Based on the group frequencies, relative intensities and Raman depolarization measurements, some vibrational assignments have been suggested. For both m... |
|
|
Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 877(10) , 857-66, (2009) BNP7787 (disodium 2,2'-dithio-bis ethane sulfonate; Tavocept) is a novel water-soluble investigational agent that is undergoing clinical development for prevention and mitigation of cisplatin-induced nephrotoxicity. BNP7787 is a disulfide that undergoes thiol... |
|
|
BNP-7787 (BioNumerik/Baxter Oncology/Grelan).
IDrugs 7(1) , 64-9, (2004) BioNumerik Pharmacology Inc, Baxter Oncology GmbH (formerly ASTA Medica AG) and Grelan Pharmaceutical Co Ltd are developing BNP-7787 for the potential reduction of toxicity associated with cisplatin and carboplatin treatment in cancer patients. |
|
|
BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro.
Mol. Cancer Ther. 9(9) , 2558-67, (2010) Taxane and platinum drugs are important agents in the treatment of cancer and have shown activity against a variety of tumors, including ovarian, breast, and lung cancer, either as single agents or in combination with other chemotherapy drugs. However, a seri... |
|
|
Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
Cancer Chemother. Pharmacol. 51(5) , 376-84, (2003) BNP7787 (disodium 2,2'-dithio-bis-ethane sulfonate) was evaluated in a phase I clinical trial with paclitaxel and cisplatin to assess the safety and potential efficacy for preventing or reducing cisplatin- and paclitaxel-induced toxicities. During this trial ... |
|
|
Accumulation of BNP7787 in human renal proximal tubule cells.
J. Pharm. Sci. 100(9) , 3977-84, (2011) BNP7787, an investigational drug undergoing global Phase III development, appears to have potential advantages over other cytoprotective compounds that have been evaluated for preventing and mitigating cisplatin-induced nephrotoxicity. Herein, we characterize... |